ABSTRACT
The European regenerative medicine patent landscape of 2010 is dense, complex, fragmented, and exploding. Legal developments in connection with human embryos may divide the two dominant institutions: the European Union (EU) and the European Patent Organisation. However, technical progress has reduced the signi–- cance of human embryonic cells. Induced pluripotent stem (iPS) cells have moved to the fore, bringing with them new issues. Meanwhile, reprogramming patents
16.1 A Moving Target ........................................................................................... 239 16.2 European Patent Environment ......................................................................240
